Recent insights into the pathophysiology of narcolepsy type 1

• Published in: Sleep medicine reviews Vol. 78; p. 101993
• Main Authors: Vringer, Marieke, Zhou, Jingru, Gool, Jari K., Bijlenga, Denise, Lammers, Gert Jan, Fronczek, Rolf, Schinkelshoek, Mink S.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-12-2024
• Subjects: Animal models; Autoimmunity; Genetics; Hcrt; Hypocretin; Immune system; Narcolepsy; Narcolepsy type 1; Neuroimaging; NT1; Autoimmunity; Neuroimaging; Animal models; Narcolepsy type 1; Genetics; NT1; Narcolepsy; Hypocretin; Hcrt; Immune system
• ISSN: 1087-0792; 1532-2955; 1532-2955
• DOI: 10.1016/j.smrv.2024.101993

Narcolepsy type 1 (NT1) is a sleep-wake disorder in which people typically experience excessive daytime sleepiness, cataplexy and other sleep-wake disturbances impairing daily life activities. NT1 symptoms are due to hypocretin deficiency. The cause for the observed hypocretin deficiency remains unclear, even though the most likely hypothesis is that this is due to an auto-immune process. The search for autoantibodies and autoreactive T-cells has not yet produced conclusive evidence for or against the auto-immune hypothesis. Other mechanisms, such as reduced corticotrophin-releasing hormone production in the paraventricular nucleus have recently been suggested. There is no reversive treatment, and the therapeutic approach is symptomatic. Early diagnosis and appropriate NT1 treatment is essential, especially in children to prevent impaired cognitive, emotional and social development. Hypocretin receptor agonists have been designed to replace the attenuated hypocretin signalling. Pre-clinical and clinical trials have shown encouraging initial results. A better understanding of NT1 pathophysiology may contribute to faster diagnosis or treatments, which may cure or prevent it.